GMAB Upgraded by JP Morgan -- Rating Raised to Overweight

gurufocus.com · 2026-10-26

On October 7, 2026, Genmab (GMAB) received an upgrade from JP Morgan, with analyst James Gordon changing the rating from Neutral to Overweight. This marks a pos

TickrTrends take: GMAB received an upgrade to Overweight from JP Morgan, which represents a positive shift in analyst sentiment despite TickrTrends currently assessing the stock as overvalued. The divergence between the upgrade and the overvaluation assessment suggests that investors should monitor whether the upgraded rating will attract sufficient buying interest to justify the current valuation multiples in the Healthcare sector. Valuation-focused readers should track whether GMAB's fundamentals strengthen enough to close the gap between its current market price and what TickrTrends considers fair value.

Read the full story at gurufocus.com →